Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, 40506, USA.
Department of Epidemiology and Environmental Health, University of Kentucky, Lexington, KY, USA.
Drugs Aging. 2024 Jul;41(7):623-632. doi: 10.1007/s40266-024-01130-z. Epub 2024 Jul 9.
Although gabapentin has been increasingly prescribed to older adults, the relation between gabapentin initiation and longer-term neurocognitive changes is not well understood. Thus, this study aimed to examine the association of gabapentin initiation with cognitive and motor function decline in older adult participants with cognitive impairment.
A retrospective cohort study was conducted using the National Alzheimer's Coordinating Center Uniform Data Set (2005-March 2023). Participants with cognitive impairment at the visit of gabapentin initiation (i.e., index visit) were included. Using the incidence density sampling method, up to nine non-users were randomly selected for each initiator. Cognitive decline over 1 year was defined as any increase in Clinical Dementia Rating global score (CDRGLOB) or a 1-point increase in CDR sum of boxes (CDRSB). Functional status decline over 1 year was defined as at least a 3-point increase in the Functional Activities Questionnaire (FAQ) sum or a 0.3-point increase of mean of FAQ. Motoric decline over 1 year was defined as new clinician reports of gait disorder, falls, and slowness. To mitigate confounding and selection bias, joint stabilized inverse probability of treatment weights and censoring weights were used. Analyses compared index with index + 1 and index + 2 visits.
For the study of cognitive and functional status decline, we included 505 initiators (mean age [SD] 78.8 [7.4]; male = 45%) and 4545 non-users (79.2 [7.6]; 50.1%). For the study of motor decline, we included 353 initiators (78.3 [7.2]; 42.8%) and 3177 non-users (78.5 [7.4]; 48.1%). Gabapentin initiation was not statistically associated with decline on CDRGLOB, CDRSB, FAQ sum, or mean FAQ at the index + 1 or index + 2 visits. However, gabapentin initiation was significantly associated with increased odds of new falls at the index + 2 visit (odds ratio [95% confidence interval] 2.5 [1.3, 4.6]).
Over 1 or 2 years of follow-up, gabapentin initiation was not associated with decline in cognitive or functional status but was associated with increased odds of falling among research participants with cognitive impairment.
尽管加巴喷丁已越来越多地用于老年患者,但加巴喷丁的起始使用与长期神经认知变化之间的关系尚不清楚。因此,本研究旨在探讨在认知障碍的老年参与者中,加巴喷丁起始使用与认知和运动功能下降的关系。
本研究使用国家阿尔茨海默病协调中心统一数据集(2005 年-2023 年 3 月)进行了一项回顾性队列研究。纳入在加巴喷丁起始使用(即索引就诊)时存在认知障碍的患者。使用发生率密度抽样法,为每个起始者随机选择最多 9 名非使用者。1 年内认知功能下降定义为临床痴呆评定量表(CDR)总体评分(CDRGLOB)增加任何程度或 CDR 框总和(CDRSB)增加 1 分。1 年内功能状态下降定义为功能活动问卷(FAQ)总和增加至少 3 分或 FAQ 平均值增加 0.3 分。1 年内运动功能下降定义为新出现的临床医生报告步态障碍、跌倒和运动迟缓。为了减轻混杂和选择偏倚,使用联合稳定的逆概率治疗权重和删失权重。分析比较了索引就诊与索引就诊+1 次就诊和索引就诊+2 次就诊。
在认知和功能状态下降的研究中,我们纳入了 505 名起始者(平均年龄[标准差]78.8[7.4];男性=45%)和 4545 名非使用者(79.2[7.6];50.1%)。在运动功能下降的研究中,我们纳入了 353 名起始者(78.3[7.2];42.8%)和 3177 名非使用者(78.5[7.4];48.1%)。在索引就诊+1 次就诊和索引就诊+2 次就诊时,加巴喷丁起始使用与 CDRGLOB、CDRSB、FAQ 总和或 FAQ 平均值均无统计学意义上的相关性。然而,在索引就诊+2 次就诊时,加巴喷丁起始使用与新发跌倒的可能性增加相关(比值比[95%置信区间]2.5[1.3, 4.6])。
在 1 年或 2 年的随访中,加巴喷丁起始使用与认知或功能状态下降无关,但与认知障碍研究参与者跌倒的可能性增加相关。